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Vimentin exhibits a complex pattern of developmental and tissue-specific expression regulated by such growth factors as TGFβ1, PDGF, FGF,
EGF and cytokines. Vimentin is expressed in the more migratory, mesenchymal cell and its expression is often down-regulated to make way for
tissue-specific intermediate filaments proteins such as desmin in muscle. Here, we suggest a mechanism to explain how TGFβ1 contributes to the
up-regulation of vimentin expression while blocking myogenesis. TGFβ1 binds to serine/threonine kinase receptors resulting in the
phosphorylation of Smad2 and Smad3, followed by formation of a heteromeric complex with Smad4. The translocation of this complex to the
nucleus modulates transcription of selected genes such as vimentin. However, the vimentin gene lacks a consensus TGFβ1 response element. By
transient transfection analysis of vimentin's various promoter elements fused to the CAT reporter gene, we have determined that tandem AP-1 sites
surrounded by GC-boxes are required for TGFβ1 induction. Mutations within this region eliminated the ability of Smad3 to induce reporter gene
expression. DNA precipitation and ChIP assays suggest that c-Jun, c-Fos, Smad3 and Sp1/Sp3 interact over this region, but this interaction
changes during myogenesis with TGFβ1 induction.
© 2006 Elsevier B.V. All rights reserved.Keywords: Smad3; c-Jun; c-Fos; AP-1 family; Sp1; TGFβ1; Vimentin; Myogenesis1. Introduction
Transforming growth factor-beta1 (TGFβ1) is an important
regulator of cell growth and differentiation in development and
cancer where it is proposed to act as a tumor suppressor at least
for early stages of cancer [1]. TGFβ1 functions by binding to a
complex of transmembrane receptor serine/threonine kinases,
which induces phosphorylation of the Type I receptor (GS
segment) by the Type II receptor [2]. Receptor complex
activation results in the C-terminal phosphorylation of Smad2
and Smad3 at selected serine residues. Two receptor-activated
Smads (R-Smads) form heteromeric complexes with Smad4, a
common Smad family member partner for the R-Smads. The⁎ Corresponding author. Tel.: +1 804 828 8753; fax: +1 804 828 1473.
E-mail address: zezehner@vcu.edu (Z.E. Zehner).
0167-4889/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2006.11.017Smad complex then translocates to the nucleus, where it
activates transcription through physical interaction and func-
tional cooperation with DNA-binding factors, such as Sp1 or
AP-1 family members, or co-activators such as the CREB-
binding protein (CBP) and p300 [2].
The TGFβ family has been shown to be potent inhibitors of
terminal differentiation in cultured myoblasts [3,4]. This
suppression blocks the expression of MyoD and myogenin,
two members of the bHLH family, thereby inhibiting
myogenesis in skeletal muscle cell lines [5]. Smad3 has been
shown to bind to the bHLH region of MyoD interfering with
MyoD/E protein dimerization and subsequent cooperative
binding to E-box DNA [7]. Smad3 also has the ability to
interact with MEF2. This interaction prevents the association of
the MyoD/E-47 dimer with MEF2 resulting in the repression of
muscle-specific gene expression following TGFβ1 treatment
[8]. Not only does TGFβ1 treatment block the expression of
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systems where MyoD or myogenin is overexpressed, indicating
an additional post-transcriptional means of repressing muscle-
specific genes [5,6].
Of the three cytoskeletal networks in eukaryotic cells the
intermediate filaments (IFs) are the most complex and least
well understood. The IF protein family (IFP) includes a variety
of proteins found in the cyptoplasm such as the cytokeratins,
glial fibrillary acidic protein (GFAP), desmin, vimentin,
neurofilaments, internexin, nestin and peripherin as well as
the lamins found in the nucleus [9,10]. Within the IFP family,
vimentin exhibits a complex pattern of tissue- and develop-
mental-specific expression. During development vimentin is
first expressed in mesodermal cells located between the
primitive streak and the proximal endoderm [11]. Initially, it
is widely expressed in the embryo, but is progressively
restricted to fewer cell types during terminal differentiation.
For example, it is expressed in early stages of muscle or
astrocyte development, but is “turned off” during differentia-
tion to make way for the tissue-specific IFPs, desmin and
GFAP, respectively [12,13]. This down-regulation is thought to
be due at least in part to the transcriptional repressor, ZBP-89
[14,15]. Vimentin expression is also regulated by cell-cycle
[16,17], growth factors (TGFβ1, PDGF, FGF) [16,18] and
cytokines such as INF-γ [19]. In addition, the vimentin gene is
up-regulated in cells that have transgressed through the
epithelial–mesenchymal transition and many metastatic tumors
despite their embryological origin [20,21]. Thus, it is important
to determine how the vimentin gene is selectively down-
regulated during the terminal differentiation of some tissues
like muscle; remains expressed in others, or is aberrantly
expressed in many metastatic tumor cells. Moreover, how is the
vimentin gene regulated by growth factors such as TGFβ1,
which impact on cell differentiation?
At present several cis-elements and associated factors have
been identified within the human vimentin promoter (see Fig.
2A). These include a TATA-box, eight putative GC-boxes
[22], a NF-κB site (−239 to −224) [23], a PEA3-binding site
(−173 to −159) [24], a DNA binding site referred to as Δ19
(−349 to −329) [25] and at least two copies of a negative
element (PS: at −329 to −289 and −645 to 631) [14].
Further upstream (at −765 and −751) are tandem AP-1
binding sites [26] and the antisilencer element, ASE [27].
The AP-1 family is composed of basic, leucine zipper (bZIP)
proteins that can form either homo- or heterodimers with
other family members and bind to AP-1 sites in the vimentin
promoter to directly activate gene expression [26]. In
addition, c-Jun and its dominant negative mutant, TAM67,
can further activate vimentin gene expression by interacting
with Sp1 and enhance binding to GC-box1 [28]. Given this
large number of interactive partners, the AP-1 family is able
to mediate the expression of a vast number of genes that
affect development as well as tumor progression. Ectopic
expression of c-Jun, v-Jun and JunB in myogenic cells has
been shown to inhibit muscle differentiation [29,30]. There-
fore, the down-regulation of c-Jun during myogenesis and/or
a change in its binding partners may be important to themyogenic program [31]. In the present study, we demonstrate
that TGFβ1 treatment of skeletal C2C12 myogenic cells not
only prevents the down-regulation of vimentin, but actually
increases vimentin expression. Yet the vimentin gene does
not contain any known TGFβ1 response element. An
investigation into this regulatory mechanism suggests that
tandem AP-1 elements located upstream of the transcription
start site are required. However, this region binds a number
of factors in addition to c-Jun and c-Fos notably Smad3 and
Sp1/Sp3. We show that the unique association of these
multiple factors is required to mediate the transcriptional
changes in vimentin expression in response to TGFβ1
treatment.
2. Materials and methods
2.1. Cell cultures
C2C12 myoblast cells (ATCC) were maintained in high-glucose D-MEM
(Invitrogen Corporation) growth medium (GM) with glutamine, supplemented
with 15% FBS, penicillin (100 units/ml) and streptomycin (50 μg/ml). Sub-
confluent cells were switched to differentiation medium (DM) containing 2%
horse serum to initiate differentiation to myotubes. Cells were treated with 1 ng/
ml TGFβ1 (Sigma) in either GM or upon switching to DM for 4 days prior to
harvesting. COS-1 cells (ATCC) were maintained in high-glucose DMEM as
above, but with 10% FBS.
2.2. RNA extraction, Northern analysis and real time PCR
Total RNA was extracted from C2C12 myoblasts, myotubes and TGFβ1
treated cells cultured as described above. Northern blots were carried out as
previously described [32]. For PCR amplification, data acquisition and analysis
were carried out by a LightCycler instrument using LightCycler 5.3.2 software
(Roche, Mannheim, Germany). The SYBR green real-time PCR assay was
carried out in 20 μl PCR mixture volume consisting of 0.3 μl Taq platinum DNA
polymerase (Invitrogen), 0.5 μl SYBR, 0.4 μl of a 10 μM dNTP mix and 2 μl of
cDNA. The primer sequences for actin were 5′-AAACTGGAACGGT-
GAAGGTG-3′ and 5′-AGAGAAGTGGGGTGGCTTTT-3′ and for vimentin
5′-AGGAAATGGCTCGTCACCTTCGTGAATA-3′ and 5′-GGAGTGTCGG-
TTGTTAAGAACTAGAGCT-3′. Actin gene amplification was carried out as
follows: 95 °C for 15 min, and then 50 cycles in 3 steps: 94 °C for 15 s, 55 °C for
20 s, 72 °C for 15 s. At the end of the amplification cycles, melting temperature
analysis was carried out by a slow increase in temperature (0.1 °C/s) up to 95 °C.
Amplification of the vimentin gene was the same as for the actin gene except for
the annealing temperature (58 °C) and elongation time (20 s). Experiments were
carried out in triplicate and the standard error is shown. PCR products were
analyzed on a 2% agarose gel by ethidium bromide staining.
2.3. Plasmids
Various 5′-deletions (−775/+72,−725/+72,−353/+72,−319/+72,−261/
+72) and site-mutated constructs (−775/+72 mAP-1) of the human vimentin
promoter were fused to the CAT reporter gene as previously described (Fig. 2A)
[14,28,33,34]. The numbered base defining the 5′-end of some of these
constructs has been changed from previous publications to correct for
approximately 50 bp incorrectly deleted from the first published sequence of
the human vimentin promoter [16]. N-terminal Flag-tagged Smad3 and its
truncated mutants (Smad3NL, Smad3LC, Smad3C) plus the constitutively
active (TβRI-T204D) and dominant negative (TβRI-L45) TGF-β receptors
were described previously [35,36]. Other plasmids were kindly provided as
follows: pCMV-c-Jun and its mutants (TAM67, DBM-3, LZM-1) by Dr.
Michael Birrer (NCI/NIH); E1A expression plasmids [E1A12S.WT,
E1A.12S.Δ2–36, E1A.12S.Y/H(47/928)] [37] from Dr. Anton Krumm (Fred
Hutchinson Cancer Research Center), and pcDNA3Z+/cFos from Dr. Tim Bos
(Eastern Virginia Medical School).
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COS-1 and C2C12 cells were transiently transfected using the calcium
phosphate/DNA co-precipitation methods. Cells (2×105) were plated in a six-
well plate, incubated at 37 °C overnight, and transfected with DNA (1 μg),
keeping the total amount of transfected DNA constant by adding empty vector.
Forty-eight h after transfection, cell lysates were prepared using the freeze/thaw
method. pCMV-β-gal was co-transfected to serve as an internal control for
transfection efficiency. β-galactosidase activities and CAT assays were
performed according to the established protocol of Promega.
2.5. Whole cell extract preparation
Whole Cell Extracts (WCE) were prepared from COS-1 cells transiently
transfected with Flag-Smad3, c-Jun, or c-Fos by the freeze/thaw method. WCEs
for immunoprecipitation and western blots were prepared by resuspending the
cells in 1× lysis buffer [20 mM HEPES, pH 7.9, 150 mM NaCl, 1.5 mMMgCl2,
0.2 mM EDTA, 10% glycerol (vol/vol), 0.5 mM phenylmethylsulfonylfluoride,
1 mM orthovanadate and protease inhibitor cocktail (Sigma) at 10 μl/1 ml
extract]. The protein concentration was measured using the BCA Protein Assay
Kit (Pierce).
2.6. Immunoprecipitation and Western blots
WCE (1 mg) was mixed with antibody (5 μg) and 50 μl of protein A/G
PLUS-agarose in 1× lysis buffer as described above and incubated with rocking
overnight at 4 °C. The beads were washed three times with RIPA buffer (50 mM
Tris–HCl, pH 7.5, 1% NP-40 (vol/vol), 150 mM NaCl, and 0.5% sodium
deoxycholate). Antigen–antibody complexes were separated from the beads by
boiling in 1× SDS sample buffer. The proteins were separated on a 10% SDS-
PAGE gel and electrophoretically transferred to nitrocellulose. The membrane
was blocked in 1× TBST buffer (25 mM Tris, pH 7.5, 137 μM NaCl, and
2.7 mM KCl) with 5% non-fat milk for 1 h at room temperature, and then
incubated with primary antibody for 1 h at 37 °C. The membrane was washed
three times in 1× TBST buffer and incubated with horseradish peroxidase
conjugated secondary antibody. The specific antigen–antibody interactions were
detected using an ECL kit (Amersham). Antibodies used for immunoprecipita-
tion and western blot (1:1000) are as follows: monoclonal anti-β-actin antibody
(A1978), anti-Flag antibody (F3165), and anti-vimentin (V6630) from Sigma-
Aldrich; and polyclonal anti-c-Jun (D) (sc-44), anti-MHC (sc-20641), anti-
myogenin (sc-576), anti-tubulin (sc-9104) and anti-c-Fos (sc-1694) from Santa
Cruz.
2.7. DNA precipitation assays
COS-1 cells transfected with plasmids containing Flag-tagged Smad3,
pCMV-c-Jun or pCMV-c-Fos were harvested in 1× lysis buffer (10 mM HEPES,
pH 7.9, 100 mMKCl, 5 mMMgCl2, 10% glycerol, 1 mMDTT, 0.1% Nonidet P-
40, and phosphatase and protease inhibitor cocktails from Sigma-Aldrich). Cell
debris was removed by centrifugation twice for 10 min at 12,000×g at 4 °C. Cell
extracts were incubated with 1 μg of biotinylated double-strand oligonucleotides
(dsDNA) corresponding to the wild-type or mutant AP-1 site in the vimentin
promoter. Oligonucleotide sequences used are as follows: WT/AP-1; 5′-
GGGCGCGGTGAGTCACCGCCGGTGACTAAGCGACCCC-3′, mAP-1; 5′-
GGGCGCGGCACGTCACCGCCGGCACCTAAGCGACCCC-3′, and mSp1;
5′-GATCAGTATGAGTCAATGAAGATGACTAAGTACTAGA-3′. All oligo-
nucleotides were labeled with biotin at the 5′-end. The DNA affinity precipitation
assay (DAPA) was performed as described above, except that StreptAvidin
MagneSphere Paramagnetic Particles (SA-PMPs) replaced streptavidin–agarose.
2.8. ChIP assay
C2C12 myoblast cells were either harvested or allowed to differentiate for
4 days without or with TGFβ1 treatment (1 ng/ml). Proteins were cross-linked to
DNAwith 1% formaldehyde at 37 °C for 15 min. Cross-linking was stopped by
the addition of glycine to a final concentration of 125 mM at room temperature
for 5 min. Cell pellets were resuspended in lysis buffer (1% SDS, 10 mM EDTA,50 mM Tris–HCl, pH 8.1, with protease inhibitor cocktail from Sigma-Aldrich).
Pellets were sonicated 4 times at 30 s each at a submaximal input followed by
centrifugation for 10 min at 12,000 rpm. Supernatants were collected and diluted
in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, and 20 mM
Tris–HCl, pH 8.1) followed by immunoclearing with salmon sperm DNA/
Protein A agarose for 2 h at 4 °C. Immunoprecipitation was performed overnight
at 4 °C with 1 μg of anti-Smad3 antibody (Zymed Lab Inc. Cat #51-1500), c-Jun
(sc-1694X), c-Fos (sc-52X), Sp3 (sc-644X), Sp1 (sc-59X) or normal rabbit IgG
antibody from Santa Cruz. Following immunoprecipitation, 60 μl of salmon
sperm DNA/Protein A agarose was added, and then incubated for another 1 h at
4 °C. Sepharose beads were washed sequentially for 10 min each in low salt
immune complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA,
20 mM Tris–HCl, pH 8.1, and 150 mM NaCl), high salt immune complex wash
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris–HCl, pH 8.1,
and 500 mM NaCl), and LiCl immune complex wash buffer (0.25 M LiCl, 1%
NP-40, 1% deoxycholate, 1 mM EDTA, and 10 mM Tris–HCl, pH 8.1). Beads
were then washed 3 times with TE buffer and extracted twice with a total of
500 μl of elution buffer (1% SDS, 0.1 MNaHCO3). 5 MNaCl (20 μl) was added
to the eluants, which were then heated at 65 °C for 4 hr to reverse the
formaldehyde cross-linking. After reversing the cross-linking, 10 μl of 0.5 M
EDTA, 20 μl of 1 M Tris–HCl, pH 6.5 and 2 μl of 10 mg/ml Proteinase K was
added to the eluants and incubated for 1 h at 45 °C. DNA recovery was
performed by phenol/chloroform extraction and ethanol precipitation with the
addition of glycogen (20 μg) as inert carrier. The pellets were then washed with
70% ethanol and allowed to air dry. The pellets were resuspended in 20 μl TE
buffer. For PCR, 1 μl out of the 20 μl of extracted DNAwas used in 30 cycles of
amplification. The primer sequences were as follows: 5′-GGGCTCCATGAGT-
CATATCC-3′ and 5′-ATCTGGCTCAAGACCTTTGC-3′. The resulting PCR
product was 160 bp in length.3. Results
3.1. Tandem AP-1 elements are involved in blocking the decline
in vimentin expression by TGFβ1 in C2C12 cells during
myogenesis
Previously, TGFβ1 has been shown to inhibit the differ-
entiation of C2C12 myoblasts into myotubes [3,4]. Normally,
vimentin gene expression is “turned off” during myogenesis to
make way for the muscle-specific IFP, desmin [13,38]. Thus, we
wanted to determine if TGFβ1 blocks the normal decline in
vimentin gene expression [39]. C2C12 cells were cultured in
growth medium with high serum (GM) to mimic myoblast
conditions or in low serum (DM) to promote myotube
differentiation for 4 days minus or plus TGFβ1 (Fig. 1A). In
the absence of TGFβ1, C2C12 myoblasts begin to fuse to
myotubes by day 2 and continue fusing at day 4. The inclusion
of TGFβ1 in DM greatly reduces myogenic differentiation both
in 2 and 4 day cultures. Western blots of WCEs confirm the
induction of muscle-specific proteins such as myosin heavy
chain (MHC) and myogenin with myotube formation (Fig. 1B)
whereas there is little change noted in tubulin expression.
However, TGFβ1 treatment blocks the expression of the
myogenic proteins. As expected, vimentin expression remains
high in myoblasts grown in GM minus or plus TGFβ1,
decreases drastically upon myogenic differentiation, but
remains expressed in myotubes treated with TGFβ1. Both
real-time PCR and Northern blot analysis confirm that the
reduction in vimentin gene expression upon differentiation to
myotubes is alleviated by TGFβ1 treatment whereas the control
GAPDH showed little difference (Fig. 1C and D). In fact,
Fig. 1. TGFβ1 reverses the decline in vimentin gene expression during C2C12 differentiation. (A) C2C12 cells grown in DMEM medium plus 15% FBS (growth
medium, GM) or 2% horse serum (differentiation medium, DM) without or with TGFβ1 (1 ng/ml) for 2 or 4 days. (B) Western blot analysis of WCEs (50 μg) isolated
from C2C12 cells as grown in panel A for 4 days and described in Materials and methods. (C) Northern blot analysis of total RNA (20 μg) isolated from C2C12 cells
grown in GM or DM minus or plus TGFβ1 for 4 days as previously described [32]. The nitrocellulose membrane was first hybridized with a 32P-labeled human
vimentin cDNA probe (bottom) and then the membrane was stripped and re-probed with a 32P-labeled GADPH cDNA (middle). Another sample of total RNA (5 μg)
was stained with ethidium bromide to verify the integrity of the RNA (Top). (D) Total RNA (100 ng) was reverse-transcribed into cDNA using poly-dT as a primer
followed by the use of 1/20 of this sample for real-time PCR analysis. The data were normalized to adolase gene expression. The y-axis represents the relative mRNA
levels of the vimentin gene. Results are the average of three separate experiments performed in triplicate with bars representing the standard error.
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mRNA expression in both myoblasts and myotubes.
Although the vimentin gene is up-regulated by TGFβ1
treatment, a screen of the human vimentin promoter region
failed to locate a canonical TGFβ1 response element (Fig. 2A).
Therefore, transient transfections of various vimentin gene
promoter fragments (defined as a negative number representing
the unique 5′-end nucleotide to +72 and identified as vertical
arrows) fused to the reporter gene CAT were performed in
C2C12 myoblasts (MBs) versus myotubes (MTs) (Fig. 2B). In
myoblasts a typical expression pattern was noted as detected in
nonmuscle cells like HeLa [14]. The proximal promoter regionin construct −261CAT gave substantial reporter gene activity.
Inclusion of the negative element, PS, in −319CAT showed
reduced activity. Considerable activity was restored by the
addition of the adjacent Δ19 enhancer element [13,14], which
was completely eliminated by inclusion of another copy of the
PS element found in −725CAT [40]. The addition of DNA up to
−775 restored CAT activity almost to those levels displayed by
the proximal promoter region alone. Thus, it appears that the
positive factors, Sp1/Sp3 and c-Jun, which have been shown to
bind to their respective elements and promote vimentin gene
expression as well as the repressor ZBP-89, which binds the
PS elements are present in myoblasts [14,33,41]. However,
Fig. 2. TGFβ1 and Smad3 promote vimentin reporter gene activity in C2C12 cells via the tandem AP-1 elements. (A) Schematic diagram of the human vimentin
promoter depicting its various cis-elements. The negative numbers (marked by a vertical arrow) indicate the 5′-end of different vimentin promoter constructs, which
extend to +72 at the 3′-end, fused to the reporter gene, CAT. The transcriptional start site is noted by a horizontal arrow at +1. (B) Various vimentin promoter CAT
constructs (−775CAT, −725CAT, −353CAT, −319CAT and −261CAT) were transiently transfected into C2C12 cells. Myoblast cells (MB) maintained in growth
medium were harvested 48 h after transfection whereas myotubes (MT) were harvested 72 h after transfection and transfer to differentiation medium. Reporter gene
activity was normalized to co-transfected beta-galactosidase as an internal control. Results are the average of three separate experiments performed in triplicate and
bars represent the standard error. (C) Vimentin promoter construct −775CATwas transiently transfected into C2C12 cells with or without Smad3 expression plasmids
as indicated. Cells were grown in either GM or DM without or with TGFβ1 as indicated. Reporter gene activity was measured as above. (D) The −775CAT or
−775mAP-1CAT construct containing mutant tandem AP-1 sites was transfected into C2C12 myoblasts with either the empty vector or vector containing Smad3
without or with TGFβ1 as indicated. See Fig. 4B for sequence of the AP-1 and mAP-1 region. Reporter gene activity was measured as above. (E) Schematic structure
of Smad3 indicating its deletion mutants. (F) The −775CAT construct was transiently transfected into C2C12 myoblasts with either the empty vector or vector
expressing Smad3 or mutants thereof (Smad3NL or Smad3C) as indicated. Reporter gene activity was measured as above.
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proximal promoter region yields substantial reporter gene
activity. Thus, either these positive-acting factors are not present
in myotubes or they are unable to induce gene expression
[14,42,43].
Previously, Smad3 had been shown to inhibit myotube
differentiation by blocking muscle bHLH transcription factors
[7,8]. Could Smad3 be involved in the induction of vimentingene expression? To address this question, Smad3 was co-
transfected with the −775CATconstruct, which contains most of
the human vimentin promoter studied to date. In addition, this
construct contains tandem AP-1 elements (located at −765 and
−751), which have been previously shown to bind the trans-
cription factor c-Jun, a known binding partner of Smad3 [44].
C2C12 cells were cultured in growth (GM) or differentiation
(DM) medium for 4 days (Fig. 2C). In all cases co-expression
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gene activity. Interestingly, myoblasts grown in high serum GM
yield comparable CAT activity to cells treated with TGFβ1 for
4 days (Fig. 2C). Additional transient transfection analyses
demonstrate that Smad3 induction is dependent upon the tandem
AP-1 elements as mutation of these elements reduces gene
expression considerably with or without TGFβ1 treatment or
Smad3 co-transfection (Fig. 2D). Not only is Smad3 important
to TGFβ1 induction, but full-length Smad3 is required for
expression of the vimentin promoter (Fig. 2E and F). Deletion of
either the Smad3 NL- or C-domains gave activity below that of
the vector alone.
3.2. Smad3 is required for the induction of vimentin expression
in COS-1 cells
To further determine what factors might be required for the
TGFβ1 induction of vimentin expression, we chose to switch to
COS-1 cells. Since COS-1 cells are known to express low levels
of some Smad family members, we could modify Smad content
and determine what is required for TGFβ1 induction (Fig. 3A,
lane 1). In examining Smad2 and Smad3 levels, only
endogenous Smad2 could be detected on a western blot.
However, transfection with Smad2, 3, or 4 expression plasmids
yields a substantial increase in Smad protein levels (Fig. 3A,
lanes 2, 3 and 4). Since Smad4 was detected by a Flag-tag, its
endogenous level could not be monitored in lane 1. We next
determined the effect of Smad co-expression on reporter gene
activity with the −775CAT construct (Fig. 3B). CAT activity
was the highest with Smad3, less with Smad4, but returned to
Smad3 levels with co-expression of both Smad3 and 4.
Obviously, ectopic expression of Smad3 is required, but the
additional expression of Smad2 or Smad4 did not seem to be
required to attain the highest expression level under these
culture conditions. Transient transfection analysis of vimentin's
other promoter constructs in COS-1 cells alone or with Smad3
co-expression reveals low levels of reporter gene activity, only
the −775CAT construct yields high levels of activity dependent
on Smad3 co-expression, which is considerably reduced with
mutation of the AP-1 sites (Fig. 3C). Further transient
transfection analyses were performed to determine what part
of Smad3 might be important for activity of the −775CAT
construct (Fig. 3D). As found for TGFβ1 induction of vimentin
expression in C2C12 cells, full-length Smad3 is necessary, as
co-transfection of either the C-, LC- or NL-terminal truncated
Smad3 mutants (Fig. 3D) results in little activity compared toFig. 3. TGFβ1 and Smad3 promote vimentin reporter gene activity via the tandem AP
COS-1 cells transfected with vector alone (lane 1) or vector containing Smad2, Smad
actin is included as a loading control. (B) The −775CAT construct was transiently tran
or Smad4 as indicated. Reporter gene activity was measured as above. (C) Construct
were transiently co-transfected with either empty vector or the Smad3 expression plas
activity was measured as above. (D) The −775CAT construct was transiently co-tr
deletion mutants thereof (as described in Fig. 2E), and Smad3 plus a constitutively act
gene activity was measured as above. (E) Co-immunoprecipitation of Smad3 and c-J
transiently transfected with empty vector (lane 1) or Flag-Smad3 and c-Jun expressio
verified in WCEs (40 μg) in lane 2. WCEs (1 mg) were immunoprecipitated with Ig
antibodies as indicated.full-length Smad3. Moreover, CAT activity with Smad3 was
synergized by the addition of the constitutively activated
TGFβ1 receptor (TβRI-T204D), but reduced by co-transfection
with a dominant negative TGFβ1 receptor (TβRI-L45). Since it
has been shown previously that the tandem AP-1 sites in
vimentin's promoter bind and activate transcription via c-Jun,
we wanted to determine what role c-Jun might play in Smad3
activation [28]. Co-Immunoprecipitation of c-Jun with Smad3
demonstrates that there is in fact an interaction between these
two proteins (Fig. 3E, lane 4).
3.3. Smad3, c-Jun, c-Fos and Sp1 interact in a multi-protein
complex on vimentin's tandem AP-1 elements
Next, we wanted to verify that c-Jun and Smad3 were binding
to the promoter at the tandem AP-1 elements by a second
approach. Here, we choose DNA oligonucleotide precipitation
assays (DAPA) to determine what other possible proteins in
addition to c-Jun could be binding to this region. For example,
other AP-1 family members such as c-Fos have been linked to
the TGFβ1 response via an AP-1 element [45]. Indeed, c-Jun, c-
Fos and Flag-tagged Smad3 were all found to bind to the tandem
AP-1 sites (Fig. 4A). In fact overexpression of c-Fos was not
required to detect c-Fos binding as a small amount of
endogenous c-Fos was found bound with Smad3 (Fig. 4A,
lane 1). To further explore requirements for protein:DNA
binding, DAPA assays were repeated with wild type (WT) and
mutant tandem AP-1 sites (mAP-1) as defined earlier [28].
Surprisingly, when both of the tandem AP-1 sites were mutated,
there was still a measurable amount of Smad3 binding to this
region (Fig. 4B). In fact, binding was comparable with WT or
mAP-1 sites. However, it is noteworthy that c-Jun over-
expression did appear to lower the amount of Smad3 bound to
the WT compared to the mAP-1 site, additional evidence that
Smad3 and c-Jun interact off DNA [46]. A further examination
of the region around the tandem AP-1 elements revealed three
possible GC-boxes located immediately upstream, in between,
and downstream of the tandem AP-1 sites (upstream: 5′-
GGCGCGG-3′, in between 5′-CCGCCGG-3′ and downstream
5′-GCGACCCC-3′). However, there was still no apparent Smad
binding site. Since Sp1 has also been linked to TGFβ1 induction
of gene expression via interaction with Smad3, perhaps Sp1 and/
or Sp3 is also involved in expression of the vimentin gene [47].
Additional DAPAs were performed with DNA mutated for all
putative GC-boxes (Fig. 4C, mSp1) using WCEs co-transfected
with Flag-tagged Smad3, Sp1, and c-Jun. Sp1 and Smad3 as well-1 elements in COS-1 cells. (A) Western analysis of WCEs (40 μg) isolated from
3, or Smad4 cDNAs. Antibodies used for immunoblotting (IB) are indicated and
sfected into COS-1 cells with empty vector or vector expressing Smad2, Smad3
s −775CAT, −775mAP−1CAT, −725CAT, −353CAT, −319CAT, or −262CAT
mid into COS-1 cells. Cells were harvested 48 h after transfection. Reporter gene
ansfected into COS-1 cells with empty vector, or vector expressing Smad3 or
ive (TβRI-T204D) or dominant negative (TβRI-L45) TGFβ1 receptor. Reporter
un from COS-1 WCEs as described in Materials and methods. COS-1 cells were
n plasmids. Cells were harvested 48 h after transfection and protein expression
G or Flag-antibodies and immunoblotted (IB) with either c-Jun or Flag-Smad3
Fig. 4. Smad3, c-Jun, c-Fos and Sp1 assemble into a multiprotein complex on vimentin's tandem AP-1 sites. (A) WCEs were prepared from COS-1 cells transiently
transfected with the Smad3 expression plasmid alone (lane 1), plus c-Jun (lane 2) or c-Fos (lane 3). Protein expression was verified by western blot of WCE (40 μg) as
shown in the input panel. DNA precipitation assays (DAPAs) were performed with 5′-end biotinylated dsDNA containing wild-type (WT) tandem AP-1 sites
(sequence shown at bottom of panel B) incubated with WCE (500 μg) from transiently transfected COS-1 cells as indicated. After washing, bound proteins were eluted
and their content analyzed by western blot with Smad3 (Flag-tag), c-Jun or c-Fos antibodies (lower panel. (B) COS-1 cells were transiently transfected as described in
panel A with pcDNA3 vector alone or vectors containing Smad3 or c-Jun or co-transfected as labeled. Protein content of WCEs (40 μg) was analyzed in the input
panel. DAPAs were carried out with a 5′-biotinylated dsDNA containing wild type (WT) or double mutant (mAP-1) sites as shown below. Tandem AP-1 elements are
underlined. Bases changed in either mAP-1 or mSp1 are in bold and italicized. (C) DAPAs with 5′-biotinylated dsDNA containing either WT or triple mutant Sp1
(mSp1) AP-1 binding sites (sequences shown at the bottom of panel B) were conducted with WCEs isolated from COS-1 cells transiently transfected with Smad3, c-
Jun, or Sp1 separately. Western blots with the appropriate antibody confirmed protein expression (data not shown). Bound proteins were eluted and their content
analyzed by western blot with Flag-Smad3, Sp1 and c-Jun antibodies as indicated.
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and Sp1 binding to the mSp1 sequence was considerably
reduced whereas c-Jun binding remained constant. Additional
co-IP assays confirm the interaction of Sp1, c-Jun and Smad3
(data not shown) as detected previously [36].
After determining that c-Jun, c-Fos, Smad3 and Sp1/Sp3
could all be involved in the TGFβ1 induction of vimentin
expression, we wanted to determine if these factors could be
found on the endogenous vimentin promoter via ChIP assays
(Fig. 5). Western blots confirm that levels of Smad2, 3 and 4 do
not appear to vary during differentiation of myoblasts into
myotubes or with TGFβ1 treatment (data not shown).
Previously, Sp1 and Sp3 levels have been shown to decline
during myogenesis [42]. Western blots (Fig. 1B) confirm that c-
Jun levels do decline during C2C12 myogenesis. Thus, it is
possible that a switch in binding partners could occur, which in
turn would contribute to a decrease in transcription as seen for
vimentin in myotubes (Fig. 2B) [43,48]. Likewise, Western
blots reveal an increase in c-Jun levels in myotubes grown in
DM containing TGFβ1 (Fig. 1B). Chip assays reveal that
binding of Smad3, c-Jun and c-Fos to vimentin's endogenous
promoter does decline when C2C12 myoblasts differentiate to
myotubes, whereas upon TGFβ1 treatment binding increases
substantially (Fig. 5). Similarly, Sp1 and Sp3 binding appears toincrease on the endogenous promoter following TGFβ1
treatment; however, no decline is detected during myotube
differentiation despite the reported decline in Sp1/Sp3 protein
levels [42]. In fact, Sp3 binding appears to increase in myotubes
compared to myoblasts.
Since c-Jun and c-Fos were both found on the tandem AP-1
elements via DAPA assays, we wanted to determine what
would be the effect of expressing Smad3, c-Jun, c-Fos or
combinations thereof on the −775CAT construct in COS-1
cells. Surprisingly, overexpression of c-Jun alone or along with
Smad3 led to repression while overexpression of c-Fos alone or
along with Smad3 activated vimentin reporter gene expression
(Fig. 6A). Expression of these various proteins was verified by
western blots in the bottom panel. Since c-Fos is expressed at
high levels in myoblasts, perhaps the over-expression of c-Fos
in COS-1 cells mimics the activity seen in the C2C12 myoblast
reporter gene assays [31]. It has been shown that c-Fos does not
directly interact with Smad3 or 4 whereas all Jun family
members, c-Jun, JunB and JunD, do interact [46]. Moreover,
we determined which domains of c-Jun might be important for
repressing Smad3 activation. Co-transfection experiments with
the −775CAT construct reveals that the transactivation
(TAM67) or DBD-3 domains could be deleted and/or mutated
with little effect on the ability of c-Jun to repress CAT activity.
Fig. 5. ChIP assays detect differential binding of Smad3, c-Jun, c-Fos and Sp1/
Sp3 to vimentin's tandem AP-1 sites. MB, MT and MT cells grown in the
presence of TGFβ1 ?1 ng/ml) for 4 days were harvested and used for ChIP
assays as described in Materials and methods. Input lanes verify equal amounts
of DNA were used for the initial immunoprecipitation. Antibodies used for
immunoprecipitation (IP) are noted and IgG was included as a negative control.
Immunoprecipitated DNA was extracted and used for PCR with primers
encompassing the tandem AP-1 binding sites within the vimentin promoter. NC
is a negative control where template DNAwas left out of the PCR reaction. The
resulting PCR products (160 bp) were separated on a 2% agarose gel and
visualized with ethidium bromide staining. The motility of reference DNA
markers is indicated.
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of an effect (Fig. 6B). However, the expression of JDP2, an
inhibitor of c-Jun transcriptional activation, completely
repressed Smad3 activation attesting to the overall involvement
of c-Jun [49,50].
3.4. P300 is involved in Smad3′s induction of vimentin gene
expression
Smad3 has been shown to interact with the co-activator p300
to activate gene expression following TGFβ1 treatment [35,51].
In this interaction the C-terminus of Smad3 is important for
regulating the binding of CBP/p300 and this activation can be
inhibited with E1A, which interferes with p300 function. To
explore this possible relationship the −775CAT construct was
co-transfected with empty vector or vector containing Smad3
alone or plus vector containing E1A/WT (wild-type) or its
various mutants in COS-1 cells (Fig. 7A). Inclusion of E1A/WT
results in repression of Smad3 activation, while E1AMut (Δ2–
36), which lacks the N-terminal amino acids 2–36 and is
defective in interacting with p300, fails to repress Smad3
induction of the vimentin promoter [37,52]. On the other hand,
mutant E1AY/H(47,928), which lost its ability to bind Rb, but
can still bind p300, represses Smad3 activation [37,52]. Similar
results were found in C2C12 myoblasts (Fig. 7B). Furthermore,
the constitutively activated receptor, TβRI-T204D, promotes
activity equal to that of co-transfection with Smad3 alone as
seen previously in COS-1 cells (Fig. 3D). Moreover, co-
transfection of p300 alone yields a 3-fold activation over the
vector only control further substantiating a role for p300 in
enhancing vimentin expression. Western blot analysis usingWCE from these same CAT assays confirms expression of E1A
and its mutants (data not shown).
The c-Jun repressor, JDP2, has been shown to recruit
HDAC3, which can in turn repress AP-1 transcriptional
activation [53]. Here, we show that HDAC3 can interact with
regulatory factors bound to the AP-1 element and repress gene
activity of the −775CAT construct (Fig. 7C). However, this
repression can be overcome by transfecting COS-1 cells with
increasing amounts of a Smad3 expression plasmid. A western
blot using WCE from these same CAT assays confirms
expression of Smad3 and HDAC3 (data not shown).
4. Discussion
Vimentin exhibits a complex pattern of developmental- and
tissue-specific expression regulated by growth factors such as
TGFβ1. Normally, vimentin levels decline during myogenesis
to make way for the muscle-specific IFP, desmin (Fig. 1).
However, TGFβ1 treatment of C2C12 cells prevents the
reduction of vimentin gene expression as well as blocking
myogenesis. Until now, how vimentin expression is regulated
during myogenesis and the mechanism of TGFβ1 induction
was unknown. Here, we have found the location of the TGFβ1
response element to be within the AP-1 region of the vimentin
promoter (Figs. 2D and 3C). Mutation of the tandem AP-1
elements drastically reduces TGFβ1 induction via reporter gene
assays in both myogenic C2C12 and COS-1 cells. However, not
only are the AP-1 elements themselves important, but the
surrounding GC-boxes are also involved as Smad3 binding
could still be detected in DAPA assays with dsDNA containing
mutant AP-1 sites (Fig. 4) plus low levels of TGFβ1-induced
reporter gene activity are still detectable with a −775CAT
construct containing mutant AP-1 sites, but retaining the
surrounding GC-boxes (Figs. 2D and 3C). Smad3 binding
was finally eliminated with mutation of these GC-boxes. ChIP
assays further support the interaction of c-Jun, c-Fos, Smad3
and Sp1/Sp3 in mediating vimentin transcriptional activity (Fig.
5). Finally, p300 is involved in TGFβ1 induction of vimentin
transcriptional activity, which can be overcome by expression of
JDP2 or HDAC3 (Figs. 6 and 7).
Although Smad3, c-Jun, c-Fos and Sp1/Sp3 are all located in
a multiprotein complex over the AP-1 region, their relative
composition is reported to change during myogenesis. Thus, it
is not just the proximity of these binding sites, but the relative
interaction of their cognate binding factors that modulates
transcription of the vimentin gene. c-Jun (Fig. 1B) and JunD
levels have been shown to decrease during differentiation
[31,43]. Likewise, DNA binding activities as well as the level of
c-Fos and Sp1 decline [31,42,43]. It has been proposed that c-
Fos may be the preferred c-Jun binding partner during the
myoblast stage [43]. Moreover, heterodimers of c-Jun and c-Fos
have been shown to activate transcription to a greater extent
than either protein co-expressed with Smad3 alone [45]. In
contrast, c-Jun levels have been shown to decrease during
myogenesis (Fig. 1B) and it has been postulated that c-Jun or
JunD may prefer to complex with Fra2 in the myotube stage, an
interaction which maybe be enhanced by post-translational
Fig. 6. Overexpression of c-Jun represses while c-Fos synergizes vimentin expression. (A) The −775CATconstruct was co-transfected with vector alone or expression
plasmids containing Smad3, c-Jun or c-Fos alone or Smad3 plus c-Jun or c-Fos into COS-1 cells. Reporter gene assays were measured as in Fig. 2. Western blots
(shown below) confirm protein expression from the various transfections with β-actin as a loading control (B) COS-1 cells were transiently transfected with the
−775CATconstruct with vector alone or vector plus Smad3 alone or co-transfected with c-Jun, c-Jun mutants or JDP2 expression plasmids. Reporter gene assays were
measured as above. Western blots confirm protein expression with β-actin serving as a loading control. A schematic diagram of c-Jun and its various mutants is shown
below. The dominant-negative TAM67 lacks the transactivating domain. DBM-3 contains an alanine to aspartic acid substitution at residue 265, followed by a three
amino-acid insertion of negatively charged amino acids. LZM-1 lacks the C-terminal, leucine-zipper domain.
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of decent Fos antibodies excluded a complete analysis of the c-
Fos contribution to myotube gene expression. Our ChIP data
supports a decline in the c-Jun/Fos heterodimer binding to the
endogenous vimentin promoter in myotubes (Fig. 5). We
propose this change in AP-1 element binding coupled with the
presence of the transcriptional repressor ZBP-89 binding to the
two PS elements could account for the observed decline in
vimentin expression during myogenesis (Fig. 2B and C).
However, upon TGFβ1 treatment of C2C12 cells, ChIP
assays detect a dramatic increase in binding of c-Jun, c-Fos and
Sp3 with some increase in Sp1 binding to the endogenous
vimentin gene promoter (Fig. 5). DAPAs suggest that even upon
mutation of the AP-1 element, Sp1/Sp3 binding to the
surrounding GC-boxes could retain Smad3 binding to the
vimentin promoter at least in vitro (Fig. 4). While there have
been reported cases where Smad3 and c-Jun or Smad3 and Sp1can interact on a Smad3 binding site enhanced by upstream or
downstream AP-1 elements and/or GC-boxes, to our knowledge
this is the first example where TGFβ1 induction required both
such elements in lieu of a Smad3 binding site [47]. Past reports
for both collagenase and c-Jun promoters indicated that Smad
and AP-1 family members can interact synergistically [45,54].
However, there are examples where Smad3 and c-Jun ex-
pression can lead to gene repression in which case there are
often binding sites for both Smad3 and AP-1 family members
[44]. In these examples, the role of c-Fos and Sp3 is unknown
and for the vimentin promoter there is no known Smad binding
site. From our studies, we propose that Sp1 binding to the GC-
boxes surrounding the tandem AP-1 elements could serve as the
initial scaffold for DNA–protein interaction, hence binding
remains fairly constant in myoblasts and myotubes (Fig. 5). It is
only upon TGFβ1 induction that Sp3 and somewhat Sp1
binding is enhanced, which in turn supports the subsequent
Fig. 7. p300 is involved in Smad3's activation of vimentin gene expression. (A)
The −775CAT construct was co-transfected into COS-1 cells with vector alone
or vector containing Smad3 alone or plus plasmids expressing E1A/WT, E1A/
Mut (Δ2–36) or E1AY/H(47,928). E1AMut (Δ2–36) is deleted for the N-
terminal amino acids 2–36 whereas mutant E1AY/H(47,928) contains two point
mutants at amino acid position 47 and 928, which obliterates p300, but retains
Rb binding. Reporter gene activity was measured as above and results are from
three separate experiments performed in triplicate. (B) The −775CAT construct
was co-transfected into C2C12 myoblast cells as in panel Awith the addition of
the expression plasmid containing the constitutive active TGFβ1 receptor
(TbRI-T204D) or p300. Reporter gene activity was measured as in panel A. (C)
The −775CAT construct was co-transfected into COS-1 cells with Smad3 alone
or expression plasmids encoding HDAC3. Reporter gene activity was measured
as in panel A.
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thereby contributing to enhanced vimentin gene expression. In
fact, this heterocomplex may have already assembled as
suggested by IP data (Fig. 3E) and thus join the DNA as a
preformed complex [44–46]. Thus, Smad3 binding is only
completely obliterated when the surrounding GC-boxes are
mutated, yet in this case c-Jun binding is still quite apparent at
least in vitro (Fig. 4C).
Interestingly, overexpression of c-Jun in COS-1 cells
blocked Smad3 induction of vimentin reporter gene activity
whereas c-Fos synergized expression (Fig. 6A). While Smad3
has been shown to interact directly with both c-Jun and Sp1
attenuated by TGFβ1 treatment, c-Fos has not been shown to
directly interact with Smad3 [36,45,46,55]. In addition, it has
been documented that c-Jun and Smad3 can interact off DNA
[44–46]. Thus, overexpression of c-Jun could effectively lower
the amount of Smad3 available for DNA binding resulting in the
noted decreases in gene expression (Fig. 5A). In support of this
hypothesis, c-Jun and Smad3 have been shown to interact via
the leucine-zipper and N-terminal domains, respectively [56].
Mutation of the leucine zipper domain of c-Jun partially
diminished repression both in our studies (Fig. 6B) and others,
and deletion of any Smad3 domain completely abrogated
activation (Figs. 2F and 3D). Inclusion of the c-Jun inhibitor,
JPD2, completely repressed Smad3 activation (Fig. 6B). On the
other hand, c-Fos does not interact with Smad3 off DNA and
thus can synergize Smad3 activation as seen here (Fig. 6A).
Previously, Smad3 and CBP have been shown to directly
interact only after TGFβ1 treatment [35,51]. This interaction
has been linked to amino acids 210–342 of Smad3. The
inclusion of either the N- or C-terminal domains of Smad3
represses its interaction with p300 possibly by restricting the
binding of Smad3 and CBP. Furthermore, Smad3, Smad4 and
p300/CBP have been shown to interact together on the PAI-1
promoter following TGFβ1 treatment in the presence of a Smad
binding site [35]. In the case of vimentin, there is no Smad
binding site, yet we have shown via co-transfection assays that
p300 can still contribute to Smad3-dependent activation of the
vimentin promoter negating the requirement for an actual Smad
DNA-binding element (Fig. 7). Activation can only be
eliminated by co-expression of an E1A mutant (Δ2–36),
which retains the p300 interaction domain.
In contrast, the Jun dimerization protein (JDP2) is a potent
repressor of AP-1 transcriptional activity. Ectopic expression of
JDP2 by itself has been shown to induce myogenesis in C2C12
myoblasts [50]. JDP2 is an ubiquitously expressed protein that
can form stable heterodimers with c-Jun, JunB or JunD and act
as a repressor of c-Jun and the c-Jun/c-Fos heterodimers [49]. In
addition, JDP2 has been shown to inhibit the recruitment of p300
to AP-1 elements by recruiting the histone deacetylase, HDAC3
[53]. It has been proposed that JDP2 requires HDAC activity in
order to function as a repressor forming a multi-protein complex
with the known co-repressor mSin3A. In agreement, we find that
ectopic expression of JDP2 inhibits a vimentin promoter CAT
construct containing the tandem AP-1 elements (Fig. 6).
Altogether this result coupled with the fact that JDP2 levels
naturally increase during myogenesis and overexpression
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role in the down-regulation of vimentin via the recruitment of
HDAC3 [50]. This could be facilitated by the repressor function
of ZBP-89. Although interesting, additional experiments under-
standing the putative interaction of c-Jun, JPD2 and ZBP-89 in
repressing vimentin gene expression during muscle differentia-
tion is beyond the scope of this initial study.
In summary, we present a model for how TGFβ1 and its
downstream effector Smad3 might regulate vimentin gene
expression. In the absence of a Smad binding site, Sp1/3
assists in recruiting the “activated” Smad complex to
vimentin's AP-1 elements as promoted by AP-1 family
members. By interacting with c-Jun and its preferred binding
partner c-Fos, Smad3 in turn recruits p300, which could act
either as a co-activator linking the bound transcriptional factors
to the basal transcriptional machinery or exert its acetylation
activity to enhance regulatory factor activity and/or further
“open up” chromatin structure. In converse, the recruitment of
HDAC3 by JDP2 may remove acetyl groups from the basal
transcription machinery and/or an AP-1 family member
thereby resulting in repression of vimentin gene expression
during myogenesis.
Acknowledgements
This work was supported by NHLBI, National Institutes of
Health (NIH) Grant HL-45422 to Z.E.Z., DK073932 to X.L.
and an American Heart Association Mid-Atlantic Affiliate pre-
doctoral fellowship (0415464U) to M.S.
References
[1] A.B. Glick, TGFβ1, back to the future, Cancer Biol. Ther. 3 (2004)
276–283.
[2] X.-H. Feng, R. Derynck, Specificity and versatility in TGF-β signaling
through Smads, Annu. Rev. Cell Dev. Biol. 21 (2005) 659–693.
[3] J. Massague, S. Cheifetz, T. Endo, B. Nadal-Ginard, Type beta
transforming growth factor is an inhibitor of myogenic differentiation,
Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 8206–8210.
[4] E.N. Olson, E. Sternberg, J.S. Hu, G. Spizz, C. Wilcox, Regulation of
myogenic differentiation by type beta transforming growth factor, J. Cell
Biol. 103 (1986) 1799–1805.
[5] T.J. Brennan, D.G. Edmondson, L. Li, E.N. Olson, Transforming growth
factor beta represses the actions of myogenin through a mechanism
independent of DNA binding, Proc. Natl. Acad. Sci. U. S. A. 88 (1991)
3822–3826.
[6] T.B. Vaidya, S.J. Rhodes, E.J. Taparowsky, S.F. Konieczny, Fibroblast
growth factor and transforming growth factor beta repress transcription
of the myogenic regulatory gene MyoD1, Mol. Cell. Biol. 9 (1989)
3576–3579.
[7] D. Liu, B.L. Black, R. Derynck, TGF-β inhibits muscle differentiation
through functional repression of myogenic transcription factors by Smad3,
Genes Dev. 15 (2001) 2950–2966.
[8] D. Liu, J.S. Kang, R. Derynck, TGF-β activated Smad3 represses MEF2-
dependent transcription in myogenic differentiation, EMBO J. 23 (2004)
1557–1566.
[9] P.M. Steinert, R.K. Liem, Intermediate filament dynamics, Cell 60 (1990)
521–523.
[10] D.A. Parry, P.M. Steinert, Intermediate filament structure, Curr. Opin. Cell
Biol. 4 (1992) 94–98.
[11] P. Duprey, D. Paulin, What can be learned from intermediate filament gene
regulation in the mouse embryo, Int. J. Dev. Biol. 39 (1995) 443–457.[12] C.M. Sax, F.X. Farrell, Z.E. Zehner, Down-regulation of vimentin gene
expression during myogenesis is controlled by a 5′-flanking sequence,
Gene 78 (1989) 235–242.
[13] V. Moura-Neto, M.H. Kryszke, Z. Li, P. Vicart, A. Lilienbaum, D. Paulin,
A 28-bp negative element with multiple factor-binding activity
controls expression of the vimentin-encoding gene, Gene 168 (1996)
261–266.
[14] E. Wieczorek, Z. Lin, E.B. Perkins, D.J. Law, J.L. Merchant, Z.E. Zehner,
The zinc finger repressor, ZBP-89, binds to the silencer element of the
human vimentin gene and complexes with the transcriptional activator,
Sp1, J. Biol. Chem. 275 (2000) 12879–12888.
[15] R. Passantino, V. Antona, G. Barbieri, P. Rubino, R. Melchionna, G.
Cossu, S. Feo, A. Giallongo, Negative regulation of β-enolase gene
transcription in embryonic muscle is dependent upon a zinc finger factor
that binds to the G-rich box within the muscle-specific enhancer, J. Biol.
Chem. 273 (1998) 484–494.
[16] S. Ferrari, R. Battini, L. Kaczmarek, S.R. Rittling, B. Calabretta, J.K. de
Riel, V. Philiponis, J.F. Wei, R. Baserga, Coding sequence and growth
regulation of the human vimentin gene, Mol. Cell Biol. 6 (1986)
3614–3620.
[17] C.W. Gibson, S.R. Rittling, R.R. Hirschhorn, L. Kaczmarek, B. Calabretta,
C.D. Stiles, R. Baserga, Cell cycle dependent genes inducible by different
mitogens in cells from different species, Mol. Cell. Biochem. 71 (1986)
61–69.
[18] I. Carey, Z.E. Zehner, Regulation of chicken vimentin gene expression by
serum, phorbol ester, and growth factors: identification of a novel
fibroblast growth factor-inducible element, Cell Growth Differ. 6 (1995)
899–908.
[19] E.S. Izmailova, S.R. Snyder, Z.E. Zehner, A Stat1a factor regulated the
expression of the human vimentin gene by IFN-γ, J. Inter. Cytokine Res.
20 (2000) 13–20.
[20] M.J. Bussemakers, G.W. Verhaegh, A. vanBokhoven, F.M. Debruyne, J.A.
Schalken, Differential expression of vimentin in rat prostatic tumors,
Biochem. Biophys. Res. Commun. 182 (1992) 1254–1259.
[21] C. Gilles, E.W. Thompson, The epithelial to mesenchymal transition and
metastatic progression in carcinoma, Breast J. 2 (1996) 83–96.
[22] S.R. Rittling, R. Baserga, Functional analysis and growth factor regulation
of the human vimentin promoter, Mol. Cell. Biol. 7 (1987) 3908–3915.
[23] A. Lilienbaum, D. Paulin, Activation of the human vimentin gene by the
Tax human T-cell leukemia virus I: mechanisms of regulation by the NF-
κB transcription factor, J. Biol. Chem. 268 (1993) 2180–2188.
[24] J.H. Chen, C. Vercamer, Z. Li, D. Paulin, B. Vandenbunder, D. Stehelin,
PEA3 transactivates vimentin promoter in mammary epithelial and tumor
cells, Oncogene 13 (1996) 1667–1675.
[25] A. Salvetti, A. Lilienbaum, Z. Li, D. Paulin, L. Gazzolo, Identification of a
negative element in the human vimentin promoter: modulation by the
human T-cell leukemia virus type I Tax protein, Mol. Cell. Biol. 13 (1993)
89–97.
[26] S.R. Rittling, L. Coutinho, T. Amram, M. Kolbe, AP-1/jun binding sites
mediate serum inducibility of the human vimentin promoter, Nucleic Acids
Res. 17 (1989) 1619–1633.
[27] E.S. Izmailova, Z.E. Zehner, An antisilencer element is involved in the
transcriptional regulation of the human vimentin gene, Gene 230 (1999)
111–120.
[28] Y. Wu, X. Zhang, Z.E. Zehner, c-Jun and the dominant-negative mutant,
TAM67, induce vimentin gene expression by interacting with the activator
Sp1, Oncogene 22 (2003) 8891–8901.
[29] E. Bengal, L. Ransone, R. Scharfmann, V.J. Dwarki, S.J. Tapscott, H.
Weintraub, I.M. Verma, Functional antagonism between c-jun and myoD
proteins: a direct physical association, Cell 68 (1992) 507–519.
[30] L. Li, J. Zhou, G. James, R. Hellier-Harrison, M.P. Czech, E.N. Olson,
FGF inactivates myogenic helix–loop–helix proteins through phosphor-
ylation of a conserved protein kinase C site in their DNA-binding domains,
Cell 71 (1992) 1182–1194.
[31] S.K. Lehtinen, P. Rahkila, M. Helenius, P. Korhonen, A. Salminen, Down-
regulation of transcription factors AP-1, Sp-1, and NF-?B precedes
myocyte differentiation, Biochem. Biophys. Res. Commun. 229 (1996)
36–43.
439Y. Wu et al. / Biochimica et Biophysica Acta 1773 (2007) 427–439[32] X. Liu, Y. Wu, Z.E. Zehner, C.K. Jackson-Cook, J.L. Ware, Proteomic
analysis of the tumorigenic human prostate cell line M12 after microcell-
mediated transfer of chromosome 19 demonstrates reduction of vimentin,
Electrophoresis 24 (2004) 3445–3453.
[33] X. Zhang, I.H. Diab, Z.E. Zehner, ZBP-89 represses vimentin gene
transcription by interacting with the transcriptional activator, Sp1, Nucleic
Acids Res. 31 (2003) 2900–2914.
[34] Y. Wu, I. Diab, X. Zhang, E.S. Izmailova, Z.E. Zehner, Stat3 enhances
vimentin gene expression by binding to the antisilencer element and
interacting with the repressor protein, ZBP-89, Oncogene 23 (2004)
168–178.
[35] X.-H. Feng, Y. Zhang, R.-Y. Wu, R. Derynck, The tumor suppressor
Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for
Smad3 in TGF-β-induced transcriptional activation, Genes Dev. 12 (1998)
2153–2163.
[36] X.-H. Feng, X. Lin, R. Derynck, Smad2, Samd3, and Smad4 cooperate
with Sp1 to induce p15Ink4B transcription in response to TGF-β, EMBO J.
19 (2000) 5178–5193.
[37] H.-G.H. Wang, E. Moran, P. Yaciuk, E1A promotes association between
p300 and pRB in multimeric complexes required for normal biological
activity, J. Virol. 69 (1995) 7917–7924.
[38] F.X. Farrell, C.M. Sax, Z.E. Zehner, A negative element involved in
vimentin gene expression, Mol. Cell. Biol. 10 (1990) 2349–2358.
[39] Y. Li, W. Foster, B.M. Deasy, Y. Chan, V. Prisk, Y. Tang, J. Cummins, J.
Huard, Transforming growth factor-β1 induces the differentiation of
myogenic cells into fibrotic cells in injured skeletal muscle, Am. J. Pathol.
164 (2004) 1007–1019.
[40] M.H. Kryszke, V. Moura-Neto, A. Lilienbaum, D. Paulin, C. Auclair,
Involvement of histone H4 gene transcription factor 1 in downregulation of
vimentin gene expression during skeletal muscle differentiation, FEBS
Lett. 491 (2001) 30–34.
[41] E.S. Izmailova, E. Wieczorek, E.B. Perkins, Z.E. Zehner, A GC-box is
required for expression of the human vimentin gene, Gene 235 (1999)
69–75.
[42] M.B. deLeon, C. Montanez, P. Gomez, S.L. Morales-Lazaro, V. Tapia-
Ramirez, V. Valadez-Graham, F. Recillas-Targa, D. Yaffe, U. Nudel, B.
Cisneros, Dystrophin Dp71 gene expression is down-regulated during
myogenesis: Role of Sp1 and Sp3 on the Dp71 promoter activity, J. Biol.
Chem. 280 (2005) 5290–5299.
[43] J.J. Andreucci, D. Grant, D.M. Cox, L.K. Tomc, R. Prywes, D.J.
Goldhamer, N. Rodrigues, P.A. Bedard, J.C. McDermott, Composition and
function of AP-1 transcription complexes during muscle cell differentia-
tion, J. Biol. Chem. 277 (2002) 16426–16432.
[44] F. Verrecchia, L. Vindevoghel, R.J. Lechleider, J. Uitto, A.B. Roberts, A.Mauviel, Smad3/AP-1 interactions control transcriptional responses to
TGF-β in a promoter-specific manner, Oncogene 20 (2001) 3332–3340.
[45] Y. Zhang, X.-H. Feng, R. Derynck, Smad3 and Smad4 cooperate with c-
Jun/c-Fos to mediate TGF-β-induced transcription, Nature 394 (1998)
909–913.
[46] N.T. Liberati, M.B. Datto, J.P. Frederick, X. Shen, C. Wong, E.M.
Rougier-Chapman, X.F. Wang, Smads bind directly to the Jun family of
AP-1 transcription factors, Proc. Natl. Acad. Sci. U. S. A. 96 (1999)
4844–4849.
[47] G. Brodin, A. Ahgren, P. tenDijke, C.-H. Heldin, R. Heuchel, Efficient
TGF-β induction of the Smad7 gene requires cooperation between AP-1,
Sp1, and Smad proteins on the mouse Smad7promoter, J. Biol. Chem. 275
(2000) 29023–29030.
[48] G. Thinakaran, J. Ojala, J. Bag, Expression of c-jun/AP-1 during myogenic
differentiation in mouse C2C12 Myoblasts, FEBS Lett. 319 (1993)
271–276.
[49] A. Aronheim, E. Zandi, H. Hennemann, S.J. Elledge, M. Karin, Isolation
of an AP-1 repressor by a novel method for detecting protein–protein
interactions, Mol. Cell. Biol. 17 (1997) 3094–3102.
[50] O. Ostrovsky, E. Bengal, A. Aronheim, Induction of terminal differentia-
tion by the c-Jun dimerization protein JPD2 in C2 myoblasts and
rhabdomyosarcoma cells, J. Biol. Chem. 277 (2002) 40043–40054.
[51] R. Janknecht, N.J. Wells, T. Hunter, TGF-β-stimulated cooperation of
Smad proteins with the coactivators CBP/p300, Genes Dev. 12 (1998)
2114–2119.
[52] H.-G.H. Wang, Y. Rikitake, M.C. Carter, P. Yaciuk, S.E. Abraham, B.
Zerler, E. Moran, Identification of specific adenovirus E1A N-terminal
residues critical to the binding of cellular proteins and to the control of cell
growth, J. Virol. 67 (1993) 476–488.
[53] C. Jin, H. Li, T. Murata, K. Sun, M. Horikoshi, R. Chiu, K.K. Yokoyama,
JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to
inhibit the retinoic acid-induced differentiation of F9 cells, Mol. Cell. Biol.
22 (2002) 4815–4826.
[54] C. Wong, E.M. Rougier-Chapman, J.P. Frederick, M.B. Datto, N.T.
Liberati, J.M. Li, X.F. Wang, Smad3–Smad4 and AP-1 complexes
synergize in transcriptional activation of the c-Jun promoter by
transforming growth factor β, Mol. Cell. Biol. 19 (1999) 1821–1830.
[55] P.K. Datta, M.C. Blake, H.L. Moses, Regulation of plasminogen activator
inhibitor-1 expression by Transforming Growth Factor-β-induced physical
and functional interactions between Smads and Sp1, J. Biol. Chem. 275
(2000) 40014–40019.
[56] J. Qing, Y. Zhang, R. Derynck, Structural and functional characterization
of the transforming growth factor-beta-induced Smad3/c-Jun transcrip-
tional cooperativity, J. Biol. Chem. 275 (2000) 38802–38812.
